

Michael D Taylor

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/961447/publications.pdf>

Version: 2024-02-01

419
papers

47,691
citations

1893

102
h-index

2178

202
g-index

448
all docs

448
docs citations

448
times ranked

35961
citing authors

#	ARTICLE	IF	CITATIONS
1	Emergence and maintenance of actionable genetic drivers at medulloblastoma relapse. Neuro-Oncology, 2022, 24, 153-165.	1.2	28
2	Clinically Tractable Outcome Prediction of Non-WNT/Non-SHH Medulloblastoma Based on TPD52 IHC in a Multicohort Study. Clinical Cancer Research, 2022, 28, 116-128.	7.0	8
3	Radiomic signatures of posterior fossa ependymoma: Molecular subgroups and risk profiles. Neuro-Oncology, 2022, 24, 986-994.	1.2	8
4	Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency. Nature Medicine, 2022, 28, 125-135.	30.7	53
5	Myocardial Parametric Mapping by Cardiac Magnetic Resonance Imaging in Pediatric Cardiology and Congenital Heart Disease. Circulation: Cardiovascular Imaging, 2022, 15, CIRCIMAGING120012242.	2.6	9
6	The biology of ependymomas andÂemerging novel therapies. Nature Reviews Cancer, 2022, 22, 208-222.	28.4	24
7	A clinically compatible drugâ€screening platform based on organotypic cultures identifies vulnerabilities to prevent and treat brain metastasis. EMBO Molecular Medicine, 2022, 14, e14552.	6.9	12
8	Amplifying natural antitumor immunity for personalized immunotherapy. Cell Research, 2022, , .	12.0	1
9	EPEN-18. Oncogenic 3D genome conformations identify novel therapeutic targets in ependymoma. Neuro-Oncology, 2022, 24, i42-i42.	1.2	0
10	MEDB-14. Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome. Neuro-Oncology, 2022, 24, i107-i107.	1.2	1
11	MEDB-07. Long-term medical and functional outcomes of medulloblastoma survivors: a population-based, matched cohort study. Neuro-Oncology, 2022, 24, i105-i105.	1.2	0
12	LGG-58. Understanding the transcriptional heterogeneity of pediatric low-grade gliomas and its implication for tumor pathophysiology. Neuro-Oncology, 2022, 24, i101-i102.	1.2	0
13	Long-term medical and functional outcomes of medulloblastoma survivors: A population-based, matched cohort study.. Journal of Clinical Oncology, 2022, 40, 10053-10053.	1.6	0
14	Abstract 5224: The PREcision Oncology For Young peopLE (PROFYLE) Program: A national precision oncology program for children, adolescents and young adults with hard-to-cure cancer in Canada. Cancer Research, 2022, 82, 5224-5224.	0.9	1
15	Long-term medical and functional outcomes of ependymoma survivors: A population-based, matched cohort study.. Journal of Clinical Oncology, 2022, 40, 10054-10054.	1.6	0
16	The HHIP-AS1 lncRNA promotes tumorigenicity through stabilization of dynein complex 1 in human SHH-driven tumors. Nature Communications, 2022, 13, .	12.8	16
17	GLI3Âs Associated With Neuronal Differentiation in SHH-Activated and WNT-Activated Medulloblastoma. Journal of Neuropathology and Experimental Neurology, 2021, 80, 129-136.	1.7	5
18	The Transition from Quiescent to Activated States in Human Hematopoietic Stem Cells Is Governed by Dynamic 3D Genome Reorganization. Cell Stem Cell, 2021, 28, 488-501.e10.	11.1	51

#	ARTICLE	IF	CITATIONS
19	Radiation-induced intracranial aneurysm presenting with acute hemorrhage in a child treated for medulloblastoma. <i>Child's Nervous System</i> , 2021, 37, 1387-1389.	1.1	2
20	Single-cell chromatin accessibility profiling of glioblastoma identifies an invasive cancer stem cell population associated with lower survival. <i>ELife</i> , 2021, 10, .	6.0	45
21	Artificial intelligence for automatic cerebral ventricle segmentation and volume calculation: a clinical tool for the evaluation of pediatric hydrocephalus. <i>Journal of Neurosurgery: Pediatrics</i> , 2021, 27, 131-138.	1.3	17
22	Mutations in the RAS/MAPK Pathway Drive Replication Repairâ€“Deficient Hypermutated Tumors and Confer Sensitivity to MEK Inhibition. <i>Cancer Discovery</i> , 2021, 11, 1454-1467.	9.4	19
23	Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q. <i>Neuro-Oncology</i> , 2021, 23, 1360-1370.	1.2	46
24	Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 807-821.	1.6	40
25	The transcriptional landscape of Shh medulloblastoma. <i>Nature Communications</i> , 2021, 12, 1749.	12.8	47
26	Spatial concordance of DNA methylation classification in diffuse glioma. <i>Neuro-Oncology</i> , 2021, 23, 2054-2065.	1.2	19
27	Systems pharmacogenomics identifies novel targets and clinically actionable therapeutics for medulloblastoma. <i>Genome Medicine</i> , 2021, 13, 103.	8.2	10
28	Abstract 636: PROFYLE: The pan-Canadian precision oncology program for children, adolescents and young adults with hard-to-treat cancer. , 2021, , .		3
29	Subgroup and subtype-specific outcomes in adult medulloblastoma. <i>Acta Neuropathologica</i> , 2021, 142, 859-871.	7.7	34
30	Single allele loss-of-function mutations select and sculpt conditional cooperative networks in breast cancer. <i>Nature Communications</i> , 2021, 12, 5238.	12.8	8
31	Clinical phenotypes and prognostic features of embryonal tumours with multi-layered rosettes: a Rare Brain Tumor Registry study. <i>The Lancet Child and Adolescent Health</i> , 2021, 5, 800-813.	5.6	12
32	Modeling human brain tumors in flies, worms, and zebrafish: From proof of principle to novel therapeutic targets. <i>Neuro-Oncology</i> , 2021, 23, 718-731.	1.2	5
33	DNA Polymerase and Mismatch Repair Exert Distinct Microsatellite Instability Signatures in Normal and Malignant Human Cells. <i>Cancer Discovery</i> , 2021, 11, 1176-1191.	9.4	46
34	Dual role of allele-specific DNA hypermethylation within the TERT promoter in cancer. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	11
35	Re-evaluating surgery and re-irradiation for locally recurrent pediatric ependymoma â€“ a multi-institutional study. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab158.	0.7	5
36	TMOD-25. LATENT SOX9-POSITIVE CELLS BEHIND MYC-DRIVEN MEDULLOBLASTOMA RELAPSE. <i>Neuro-Oncology</i> , 2021, 23, vi220-vi221.	1.2	0

#	ARTICLE	IF	CITATIONS
37	STEM-26. BLOOD-TUMOR BARRIER IS COMPOSED OF MECHANOSENSING TUMOR CELLS THAT MASK THERAPEUTIC VULNERABILITY. <i>Neuro-Oncology</i> , 2021, 23, vi26-vi26.	1.2	0
38	Molecular correlates of cerebellar mutism syndrome in medulloblastoma. <i>Neuro-Oncology</i> , 2020, 22, 290-297.	1.2	21
39	Postoperative isolated lower extremity supplementary motor area syndrome: case report and review of the literature. <i>Child's Nervous System</i> , 2020, 36, 189-195.	1.1	3
40	The molecular biology of medulloblastoma metastasis. <i>Brain Pathology</i> , 2020, 30, 691-702.	4.1	25
41	Medulloblastoma has a global impact on health related quality of life: Findings from an international cohort. <i>Cancer Medicine</i> , 2020, 9, 447-459.	2.8	11
42	Superior Intellectual Outcomes After Proton Radiotherapy Compared With Photon Radiotherapy for Pediatric Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 454-461.	1.6	143
43	An OTX2-PAX3 signaling axis regulates Group 3 medulloblastoma cell fate. <i>Nature Communications</i> , 2020, 11, 3627.	12.8	21
44	European genetic ancestry associated with risk of childhood ependymoma. <i>Neuro-Oncology</i> , 2020, 22, 1637-1646.	1.2	16
45	Nailing a Fe-rocious form of cancer. <i>Science</i> , 2020, 369, 250-251.	12.6	2
46	Left Ventricular Magnetic Resonance Imaging Strain Predicts the Onset of Duchenne Muscular Dystrophyâ€Associated Cardiomyopathy. <i>Circulation: Cardiovascular Imaging</i> , 2020, 13, e011526.	2.6	13
47	Histone H3.3G34-Mutant Interneuron Progenitors Co-opt PDGFRA for Gliomagenesis. <i>Cell</i> , 2020, 183, 1617-1633.e22.	28.9	93
48	Genetic predisposition to longer telomere length and risk of childhood, adolescent and adult-onset ependymoma. <i>Acta Neuropathologica Communications</i> , 2020, 8, 173.	5.2	15
49	Chloride intracellular channel 1 cooperates with potassium channel EAG2 to promote medulloblastoma growth. <i>Journal of Experimental Medicine</i> , 2020, 217, .	8.5	24
50	42. IDENTIFICATION OF BRAIN METASTASIS VULNERABILITIES USING METPLATFORM. <i>Neuro-Oncology Advances</i> , 2020, 2, ii8-ii8.	0.7	0
51	H3.3 G34W Promotes Growth and Impedes Differentiation of Osteoblast-Like Mesenchymal Progenitors in Giant Cell Tumor of Bone. <i>Cancer Discovery</i> , 2020, 10, 1968-1987.	9.4	40
52	Deep Learning for Pediatric Posterior Fossa Tumor Detection and Classification: A Multi-Institutional Study. <i>American Journal of Neuroradiology</i> , 2020, 41, 1718-1725.	2.4	31
53	Neurotrophin Signaling in Medulloblastoma. <i>Cancers</i> , 2020, 12, 2542.	3.7	25
54	Outcomes of BRAF V600E Pediatric Gliomas Treated With Targeted BRAF Inhibition. <i>JCO Precision Oncology</i> , 2020, 4, 561-571.	3.0	62

#	ARTICLE	IF	CITATIONS
55	Early Lethality Due to a Novel Desmoplakin Variant Causing Infantile Epidermolysis Bullosa Simplex With Fragile Skin, Aplasia Cutis Congenita, and Arrhythmogenic Cardiomyopathy. Circulation Genomic and Precision Medicine, 2020, 13, e002800.	3.6	9
56	Reply to S.A. Milgrom et al. Journal of Clinical Oncology, 2020, 38, 2212-2213.	1.6	1
57	Eye Movements and White Matter are Associated with Emotional Control in Children Treated for Brain Tumors. Journal of the International Neuropsychological Society, 2020, 26, 978-992.	1.8	6
58	DDX3X Suppresses the Susceptibility of Hindbrain Lineages to Medulloblastoma. Developmental Cell, 2020, 54, 455-470.e5.	7.0	47
59	Pattern of Relapse and Treatment Response in WNT-Activated Medulloblastoma. Cell Reports Medicine, 2020, 1, 100038.	6.5	24
60	HDAC and MAPK/ERK Inhibitors Cooperate To Reduce Viability and Stemness in Medulloblastoma. Journal of Molecular Neuroscience, 2020, 70, 981-992.	2.3	21
61	Immunohistochemical and nanoString-Based Subgrouping of Clinical Medulloblastoma Samples. Journal of Neuropathology and Experimental Neurology, 2020, 79, 437-447.	1.7	19
62	The AHR pathway represses TGF β 2-SMAD3 signalling and has a potent tumour suppressive role in SHH medulloblastoma. Scientific Reports, 2020, 10, 148.	3.3	22
63	Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas. Cancer Cell, 2020, 37, 569-583.e5.	16.8	244
64	Clinical impact of combined epigenetic and molecular analysis of pediatric low-grade gliomas. Neuro-Oncology, 2020, 22, 1474-1483.	1.2	39
65	Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma. Nature Medicine, 2020, 26, 720-731.	30.7	141
66	Roadmap for the Emerging Field of Cancer Neuroscience. Cell, 2020, 181, 219-222.	28.9	182
67	Modeling germline mutations in pineoblastoma uncovers lysosome disruption-based therapy. Nature Communications, 2020, 11, 1825.	12.8	21
68	Metabolic Regulation of the Epigenome Drives Lethal Infantile Ependymoma. Cell, 2020, 181, 1329-1345.e24.	28.9	79
69	Medulloblastoma Arises from the Persistence of a Rare and Transient Sox2+ Granule Neuron Precursor. Cell Reports, 2020, 31, 107511.	6.4	35
70	Expression of GNAS, TP53, and PTEN Improves the Patient Prognostication in Sonic Hedgehog (SHH) Medulloblastoma Subgroup. Journal of Molecular Diagnostics, 2020, 22, 957-966.	2.8	11
71	Medulloblastomas. , 2020, , 1997-2016.		0
72	EPEN-36. THE TREATMENT OUTCOME OF PAEDIATRIC SUPRATENTORIAL C11ORF95-RELA FUSED EPENDYMOMA: A COMBINED REPORT FROM E-HIT SERIES AND AUSTRALIAN NEW ZEALAND CHILDRENâ€™S HAEMATOLOGY/ONCOLOGY GROUP. Neuro-Oncology, 2020, 22, iii315-iii315.	1.2	0

#	ARTICLE	IF	CITATIONS
73	Activated leukocyte cell adhesion molecule expression correlates with the WNT subgroup in medulloblastoma and is involved in regulating tumor cell proliferation and invasion. PLoS ONE, 2020, 15, e0243272.	2.5	2
74	MBRS-10. QUIESCENT SOX9-POSITIVE CELLS BEHIND MYC DRIVEN MEDULLOBLASTOMA RECURRENCE. Neuro-Oncology, 2020, 22, iii400-iii400.	1.2	0
75	LGG-55. OUTCOME OF BRAF V600E PEDIATRIC GLIOMAS TREATED WITH TARGETED BRAF INHIBITION. Neuro-Oncology, 2020, 22, iii377-iii377.	1.2	0
76	TBIO-15. MODELING DEVELOPMENTAL GENE EXPRESSION DYNAMICS AT CELLULAR RESOLUTION TO INTERPRET PEDIATRIC BRAIN TUMOR TRANSCRIPTIONAL PROGRAMS. Neuro-Oncology, 2020, 22, iii469-iii469.	1.2	0
77	Introduction. Pediatric brain tumor. Neurosurgical Focus, 2020, 48, E1.	2.3	1
78	Title is missing!., 2020, 15, e0243272.		0
79	Title is missing!., 2020, 15, e0243272.		0
80	Title is missing!., 2020, 15, e0243272.		0
81	Title is missing!., 2020, 15, e0243272.		0
82	Title is missing!., 2020, 15, e0243272.		0
83	Title is missing!., 2020, 15, e0243272.		0
84	Title is missing!., 2020, 15, e0243272.		0
85	Title is missing!., 2020, 15, e0243272.		0
86	ID1 Is Critical for Tumorigenesis and Regulates Chemoresistance in Glioblastoma. Cancer Research, 2019, 79, 4057-4071.	0.9	39
87	A C19MC-LIN28A-MYCN Oncogenic Circuit Driven by Hijacked Super-enhancers Is a Distinct Therapeutic Vulnerability in ETMRs: A Lethal Brain Tumor. Cancer Cell, 2019, 36, 51-67.e7.	16.8	69
88	Antitumor Activities and Cellular Changes Induced by TrkB Inhibition in Medulloblastoma. Frontiers in Pharmacology, 2019, 10, 698.	3.5	15
89	Incidence of metastatic disease and survival among patients with newly diagnosed primary CNS tumors in the United States from 2004-2013. Journal of Cancer, 2019, 10, 3037-3045.	2.5	8
90	An autocrine ActivinB mechanism drives $\text{TGF}\beta^2$ /Activin signaling in Group 3 medulloblastoma. EMBO Molecular Medicine, 2019, 11, e9830.	6.9	13

#	ARTICLE	IF	CITATIONS
91	High-resolution structural genomics reveals new therapeutic vulnerabilities in glioblastoma. <i>Genome Research</i> , 2019, 29, 1211-1222.	5.5	52
92	Identification and Analyses of Extra-Cranial and Cranial Rhabdoid Tumor Molecular Subgroups Reveal Tumors with Cytotoxic T Cell Infiltration. <i>Cell Reports</i> , 2019, 29, 2338-2354.e7.	6.4	74
93	The U1 spliceosomal RNA is recurrently mutated in multiple cancers. <i>Nature</i> , 2019, 574, 712-716.	27.8	128
94	Re-irradiation for children with recurrent medulloblastoma in Toronto, Canada: a 20-year experience. <i>Journal of Neuro-Oncology</i> , 2019, 145, 107-114.	2.9	18
95	Single-Cell Transcriptomics in Medulloblastoma Reveals Tumor-Initiating Progenitors and Oncogenic Cascades during Tumorigenesis and Relapse. <i>Cancer Cell</i> , 2019, 36, 302-318.e7.	16.8	96
96	Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas. <i>Nature Communications</i> , 2019, 10, 4343.	12.8	200
97	Upregulation of the chromatin remodeler HELLS is mediated by YAP1 in Sonic Hedgehog Medulloblastoma. <i>Scientific Reports</i> , 2019, 9, 13611.	3.3	19
98	<i>Sleeping Beauty</i> Insertional Mutagenesis Reveals Important Genetic Drivers of Central Nervous System Embryonal Tumors. <i>Cancer Research</i> , 2019, 79, 905-917.	0.9	33
99	Identification of CD24 as a marker of Patched1 deleted medulloblastoma-initiating neural progenitor cells. <i>PLoS ONE</i> , 2019, 14, e0210665.	2.5	5
100	Engineering Genetic Predisposition in Human Neuroepithelial Stem Cells Recapitulates Medulloblastoma Tumorigenesis. <i>Cell Stem Cell</i> , 2019, 25, 433-446.e7.	11.1	56
101	Reply to “Assembling the brain trust: the multidisciplinary imperative in neuro-oncology”™. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 522-523.	27.6	0
102	Subgroup-specific prognostic signaling and metabolic pathways in pediatric medulloblastoma. <i>BMC Cancer</i> , 2019, 19, 571.	2.6	40
103	IMMU-03. TUMOR NECROSIS FACTOR OVERCOMES IMMUNE EVASION IN P53-MUTANT MEDULLOBLASTOMA. <i>Neuro-Oncology</i> , 2019, 21, ii93-ii93.	1.2	1
104	Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes. <i>Acta Neuropathologica</i> , 2019, 138, 309-326.	7.7	180
105	EPEN-12. A COMMON FETAL DEVELOPMENTAL ORIGIN FOR PFA EPENDYMOMA, PFB EPENDYMOMA, AND CEREBELLAR PILOCYTIC ASTROCYTOMAS. <i>Neuro-Oncology</i> , 2019, 21, ii79-ii80.	1.2	0
106	Childhood cerebellar tumours mirror conserved fetal transcriptional programs. <i>Nature</i> , 2019, 572, 67-73.	27.8	293
107	Application of a Neural Network Whole Transcriptome-Based Pan-Cancer Method for Diagnosis of Primary and Metastatic Cancers. <i>JAMA Network Open</i> , 2019, 2, e192597.	5.9	67
108	Myc and Loss of p53 Cooperate to Drive Formation of Choroid Plexus Carcinoma. <i>Cancer Research</i> , 2019, 79, 2208-2219.	0.9	15

#	ARTICLE	IF	CITATIONS
109	Intratumoral Genetic and Functional Heterogeneity in Pediatric Glioblastoma. Cancer Research, 2019, 79, 2111-2123.	0.9	28
110	Picosecond Infrared Laser Desorption Mass Spectrometry Identifies Medulloblastoma Subgroups on Intrasurgical Timescales. Cancer Research, 2019, 79, 2426-2434.	0.9	31
111	Modulating native GABAA receptors in medulloblastoma with positive allosteric benzodiazepine-derivatives induces cell death. Journal of Neuro-Oncology, 2019, 142, 411-422.	2.9	18
112	Challenges to curing primary brain tumours. Nature Reviews Clinical Oncology, 2019, 16, 509-520.	27.6	540
113	Survival and functional outcomes of molecularly defined childhood posterior fossa ependymoma: Cure at a cost. Cancer, 2019, 125, 1867-1876.	4.1	49
114	Medulloblastoma. Nature Reviews Disease Primers, 2019, 5, 11.	30.5	376
115	Medulloblastoma in the age of molecular subgroups: a review. Journal of Neurosurgery: Pediatrics, 2019, 24, 353-363.	1.3	153
116	scRNA-seq in medulloblastoma shows cellular heterogeneity and lineage expansion support resistance to SHH inhibitor therapy. Nature Communications, 2019, 10, 5829.	12.8	77
117	Stalled developmental programs at the root of pediatric brain tumors. Nature Genetics, 2019, 51, 1702-1713.	21.4	136
118	Recurrent noncoding U1 snRNA mutations drive cryptic splicing in SHH medulloblastoma. Nature, 2019, 574, 707-711.	27.8	129
119	The molecular landscape of ETMR at diagnosis and relapse. Nature, 2019, 576, 274-280.	27.8	94
120	p53 Function Is Compromised by Inhibitor 2 of Phosphatase 2A in Sonic Hedgehog Medulloblastoma. Molecular Cancer Research, 2019, 17, 186-198.	3.4	10
121	Dual Regulatory Functions of SUFU and Targetome of GLI2 in SHH Subgroup Medulloblastoma. Developmental Cell, 2019, 48, 167-183.e5.	7.0	39
122	Craniospinal irradiation as part of re-irradiation for children with recurrent intracranial ependymoma. Neuro-Oncology, 2019, 21, 547-557.	1.2	32
123	PPAR and GST polymorphisms may predict changes in intellectual functioning in medulloblastoma survivors. Journal of Neuro-Oncology, 2019, 142, 39-48.	2.9	21
124	BM11 is a therapeutic target in recurrent medulloblastoma. Oncogene, 2019, 38, 1702-1716.	5.9	20
125	Bioinformatic Strategies for the Genomic and Epigenomic Characterization of Brain Tumors. Methods in Molecular Biology, 2019, 1869, 37-56.	0.9	4
126	MR Imaging-Based Radiomic Signatures of Distinct Molecular Subgroups of Medulloblastoma. American Journal of Neuroradiology, 2019, 40, 154-161.	2.4	87

#	ARTICLE	IF	CITATIONS
127	Infusion of 5-Azacytidine (5-AZA) into the fourth ventricle or resection cavity in children with recurrent posterior Fossa Ependymoma: a pilot clinical trial. <i>Journal of Neuro-Oncology</i> , 2019, 141, 449-457.	2.9	20
128	Leptomeningeal dissemination: a sinister pattern of medulloblastoma growth. <i>Journal of Neurosurgery: Pediatrics</i> , 2019, 23, 613-621.	1.3	29
129	A Hematogenous Route for Medulloblastoma Leptomeningeal Metastases. <i>Cell</i> , 2018, 172, 1050-1062.e14.	28.9	85
130	Characterization of a novel $OTX2$ -driven stem cell program in Group 3 and Group 4 medulloblastoma. <i>Molecular Oncology</i> , 2018, 12, 495-513.	4.6	16
131	Metastatic group 3 medulloblastoma is driven by PRUNE1 targeting NME1-TGF- β - $OTX2$ -SNAIL via PTEN inhibition. <i>Brain</i> , 2018, 141, 1300-1319.	7.6	22
132	Basal Suppression of the Sonic Hedgehog Pathway by the G-Protein-Coupled Receptor Gpr161 Restricts Medulloblastoma Pathogenesis. <i>Cell Reports</i> , 2018, 22, 1169-1184.	6.4	49
133	5-Hydroxymethylcytosine preferentially targets genes upregulated in isocitrate dehydrogenase 1 mutant high-grade glioma. <i>Acta Neuropathologica</i> , 2018, 135, 617-634.	7.7	15
134	A Novel Method for Rapid Molecular Subgrouping of Medulloblastoma. <i>Clinical Cancer Research</i> , 2018, 24, 1355-1363.	7.0	24
135	Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling. <i>Nature</i> , 2018, 553, 101-105.	27.8	170
136	DNA methylation-based classification of central nervous system tumours. <i>Nature</i> , 2018, 555, 469-474.	27.8	1,872
137	MRI Characteristics of Primary Tumors and Metastatic Lesions in Molecular Subgroups of Pediatric Medulloblastoma: A Single-Center Study. <i>American Journal of Neuroradiology</i> , 2018, 39, 949-955.	2.4	27
138	Opposing Effects of CREBBP Mutations Govern the Phenotype of Rubinstein-Taybi Syndrome and Adult SHH Medulloblastoma. <i>Developmental Cell</i> , 2018, 44, 709-724.e6.	7.0	35
139	Lateral cerebellum is preferentially sensitive to high sonic hedgehog signaling and medulloblastoma formation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 3392-3397.	7.1	34
140	miR miR on the wall, who's the most malignant medulloblastoma miR of them all?. <i>Neuro-Oncology</i> , 2018, 20, 313-323.	1.2	15
141	Differential patterns of metastatic dissemination across medulloblastoma subgroups. <i>Journal of Neurosurgery: Pediatrics</i> , 2018, 21, 145-152.	1.3	39
142	Review of molecular classification and treatment implications of pediatric brain tumors. <i>Current Opinion in Pediatrics</i> , 2018, 30, 3-9.	2.0	38
143	DNA hypermethylation within TERT promoter upregulates TERT expression in cancer. <i>Journal of Clinical Investigation</i> , 2018, 129, 223-229.	8.2	130
144	EPEN-23. MOLECULAR HETEROGENEITY AMONG PEDIATRIC POSTERIOR FOSSA EPENDYMOMA. <i>Neuro-Oncology</i> , 2018, 20, i77-i78.	1.2	0

#	ARTICLE	IF	CITATIONS
145	MBRS-14. REGULATION OF MEDULLOBLASTOMA IMMUNOGENICITY BY TP53 AND TNF ALPHA. Neuro-Oncology, 2018, 20, i131-i131.	1.2	0
146	A functional genomics approach to identify pathways of drug resistance in medulloblastoma. Acta Neuropathologica Communications, 2018, 6, 146.	5.2	10
147	Significance of molecular classification of ependymomas: C11orf95-RELA fusion-negative supratentorial ependymomas are a heterogeneous group of tumors. Acta Neuropathologica Communications, 2018, 6, 134.	5.2	74
148	Notch1 regulates the initiation of metastasis and self-renewal of Group 3 medulloblastoma. Nature Communications, 2018, 9, 4121.	12.8	36
149	How do parents and providers trade-off between disability and survival? Preferences in the treatment of pediatric medulloblastoma. Patient Preference and Adherence, 2018, Volume 12, 2103-2110.	1.8	1
150	A homing system targets therapeutic T cells to brain cancer. Nature, 2018, 561, 331-337.	27.8	36
151	Developmental phosphoproteomics identifies the kinase CK2 as a driver of Hedgehog signaling and a therapeutic target in medulloblastoma. Science Signaling, 2018, 11, .	3.6	59
152	Aberrant ERBB4-SRC Signaling as a Hallmark of Group 4 Medulloblastoma Revealed by Integrative Phosphoproteomic Profiling. Cancer Cell, 2018, 34, 379-395.e7.	16.8	104
153	Reproducibility of the NanoString 22-gene molecular subgroup assay for improved prognostic prediction of medulloblastoma. Neuropathology, 2018, 38, 475-483.	1.2	26
154	The clinical importance of medulloblastoma extent of resection: a systematic review. Journal of Neuro-Oncology, 2018, 139, 523-539.	2.9	43
155	TGF- β 2 Determines the Pro-migratory Potential of bFGF Signaling in Medulloblastoma. Cell Reports, 2018, 23, 3798-3812.e8.	6.4	33
156	CD271+ Cells Are Diagnostic and Prognostic and Exhibit Elevated MAPK Activity in SHH Medulloblastoma. Cancer Research, 2018, 78, 4745-4759.	0.9	31
157	Proteomic analysis of Medulloblastoma reveals functional biology with translational potential. Acta Neuropathologica Communications, 2018, 6, 48.	5.2	35
158	Heterogeneity within the PF-EPN-B ependymoma subgroup. Acta Neuropathologica, 2018, 136, 227-237.	7.7	86
159	CAR T cells for childhood diffuse midline gliomas. Nature Medicine, 2018, 24, 534-535.	30.7	3
160	Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. Lancet Oncology, The, 2018, 19, 785-798.	10.7	268
161	Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas. Acta Neuropathologica, 2018, 136, 211-226.	7.7	199
162	Poliovirus Receptor (CD155) Expression in Pediatric Brain Tumors Mediates Oncolysis of Medulloblastoma and Pleomorphic Xanthoastrocytoma. Journal of Neuropathology and Experimental Neurology, 2018, 77, 696-702.	1.7	38

#	ARTICLE	IF	CITATIONS
163	MAP4K4 controlled integrin β 1 activation and c-Met endocytosis are associated with invasive behavior of medulloblastoma cells. <i>Oncotarget</i> , 2018, 9, 23220-23236.	1.8	32
164	Medulloblastoma in the Molecular Era. <i>Journal of Korean Neurosurgical Society</i> , 2018, 61, 292-301.	1.2	22
165	Medulloblastomas. , 2018, , 1-27.		0
166	Executive function in paediatric medulloblastoma: The role of cerebrocerebellar connections. <i>Journal of Neuropsychology</i> , 2017, 11, 174-200.	1.4	39
167	Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity. <i>Nature</i> , 2017, 543, 122-125.	27.8	530
168	Integrated analysis of proteome, phosphotyrosine proteome, tyrosine kinase, and tyrosine phosphatome in acute myeloid leukemia. <i>Proteomics</i> , 2017, 17, 1600361.	2.2	17
169	Spatial heterogeneity in medulloblastoma. <i>Nature Genetics</i> , 2017, 49, 780-788.	21.4	112
170	Prognostic relevance of miR-124-3p and its target <i>TP53INP1</i> in pediatric ependymoma. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 639-650.	2.8	16
171	Tailoring Medulloblastoma Treatment Through Genomics: Making a Change, One Subgroup at a Time. <i>Annual Review of Genomics and Human Genetics</i> , 2017, 18, 143-166.	6.2	24
172	Pyruvate Kinase Inhibits Proliferation during Postnatal Cerebellar Neurogenesis and Suppresses Medulloblastoma Formation. <i>Cancer Research</i> , 2017, 77, 3217-3230.	0.9	45
173	H3 K27M mutations are extremely rare in posterior fossa group A ependymoma. <i>Child's Nervous System</i> , 2017, 33, 1047-1051.	1.1	46
174	Intertumoral Heterogeneity within Medulloblastoma Subgroups. <i>Cancer Cell</i> , 2017, 31, 737-754.e6.	16.8	836
175	The role of angiogenesis in Group 3 medulloblastoma pathogenesis and survival. <i>Neuro-Oncology</i> , 2017, 19, 1217-1227.	1.2	53
176	Disrupting the CD47-SIRP α anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	306
177	Comprehensive Analysis of Hypermutation in Human Cancer. <i>Cell</i> , 2017, 171, 1042-1056.e10.	28.9	596
178	Fate mapping of human glioblastoma reveals an invariant stem cell hierarchy. <i>Nature</i> , 2017, 549, 227-232.	27.8	321
179	Drain the swamp to beat glioma. <i>Nature</i> , 2017, 549, 460-461.	27.8	4
180	Put away your microscopes: the ependymoma molecular era has begun. <i>Current Opinion in Oncology</i> , 2017, 29, 443-447.	2.4	21

#	ARTICLE	IF	CITATIONS
181	Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma. <i>Cancer Cell</i> , 2017, 32, 295-309.e12.	16.8	148
182	The whole-genome landscape of medulloblastoma subtypes. <i>Nature</i> , 2017, 547, 311-317.	27.8	787
183	Rapid determination of medulloblastoma subgroup affiliation with mass spectrometry using a handheld picosecond infrared laser desorption probe. <i>Chemical Science</i> , 2017, 8, 6508-6519.	7.4	42
184	Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome. <i>Acta Neuropathologica</i> , 2017, 134, 705-714.	7.7	168
185	Therapeutic radiation for childhood cancer drives structural aberrations of NF2 in meningiomas. <i>Nature Communications</i> , 2017, 8, 186.	12.8	76
186	Convergence of BMI1 and CHD7 on ERK Signaling in Medulloblastoma. <i>Cell Reports</i> , 2017, 21, 2772-2784.	6.4	31
187	Pontine Infantile Glioma Simplified. <i>Cancer Cell</i> , 2017, 32, 548-549.	16.8	1
188	Transposase-driven rearrangements in human tumors. <i>Nature Genetics</i> , 2017, 49, 975-977.	21.4	1
189	The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. <i>Acta Neuropathologica</i> , 2017, 133, 5-12.	7.7	271
190	MEDU-13. CONVERGENCE OF BMI1 AND CHD7 ON ERK SIGNALLING IN MEDULLOBLASTOMA. <i>Neuro-Oncology</i> , 2017, 19, iv40-iv40.	1.2	0
191	Advances in Genomics Explain Medulloblastoma Behavior at the Bedside. <i>Neurosurgery</i> , 2017, 64, 21-26.	1.1	7
192	Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas. <i>Journal of Clinical Oncology</i> , 2017, 35, 2934-2941.	1.6	232
193	Medulloblastoma: From Myth to Molecular. <i>Journal of Clinical Oncology</i> , 2017, 35, 2355-2363.	1.6	129
194	MPS1 kinase as a potential therapeutic target in medulloblastoma. <i>Oncology Reports</i> , 2016, 36, 2633-2640.	2.6	23
195	FBW7 suppression leads to SOX9 stabilization and increased malignancy in medulloblastoma. <i>EMBO Journal</i> , 2016, 35, 2192-2212.	7.8	58
196	Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. <i>Cancer Cell</i> , 2016, 30, 891-908.	16.8	191
197	Treatment implications of posterior fossa ependymoma subgroups. <i>Chinese Journal of Cancer</i> , 2016, 35, 93.	4.9	21
198	Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. <i>Acta Neuropathologica</i> , 2016, 131, 821-831.	7.7	478

#	ARTICLE	IF	CITATIONS
199	Vulnerability of white matter to insult during childhood: evidence from patients treated for medulloblastoma. <i>Journal of Neurosurgery: Pediatrics</i> , 2016, 18, 29-40.	1.3	25
200	Intellectual Outcome in Molecular Subgroups of Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 4161-4170.	1.6	72
201	Clinical, Pathological, and Molecular Characterization of Infant Medulloblastomas Treated with Sequential High-Dose Chemotherapy. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1527-1534.	1.5	94
202	Genome-Wide DNA Methylation Analysis Reveals Epigenetic Dysregulation of MicroRNA-34A in TP53-Associated Cancer Susceptibility. <i>Journal of Clinical Oncology</i> , 2016, 34, 3697-3704.	1.6	33
203	CMS-09BEHAVIOR AND TEMPERAMENT IN CHILDREN TREATED FOR PEDIATRIC MEDULLOBLASTOMA WITH POSTOPERATIVE CEREBELLAR MUTISM SYNDROME. <i>Neuro-Oncology</i> , 2016, 18, iii17.4-iii17.	1.2	0
204	PINK1 Is a Negative Regulator of Growth and the Warburg Effect in Glioblastoma. <i>Cancer Research</i> , 2016, 76, 4708-4719.	0.9	107
205	MB3W1 is an orthotopic xenograft model for anaplastic medulloblastoma displaying cancer stem cell- and Group 3-properties. <i>BMC Cancer</i> , 2016, 16, 115.	2.6	17
206	Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. <i>Journal of Clinical Oncology</i> , 2016, 34, 2468-2477.	1.6	160
207	Medulloblastoma subgroup-specific outcomes in irradiated children: who are the true high-risk patients?. <i>Neuro-Oncology</i> , 2016, 18, 291-297.	1.2	112
208	Divergent clonal selection dominates medulloblastoma at recurrence. <i>Nature</i> , 2016, 529, 351-357.	27.8	266
209	Genome-Wide Profiles of Extra-cranial Malignant Rhabdoid Tumors Reveal Heterogeneity and Dysregulated Developmental Pathways. <i>Cancer Cell</i> , 2016, 29, 394-406.	16.8	105
210	Evasion of Cell Senescence Leads to Medulloblastoma Progression. <i>Cell Reports</i> , 2016, 14, 2925-2937.	6.4	35
211	Fall of the Optical Wall: Freedom from the Tyranny of the Microscope Improves Glioma Risk Stratification. <i>Cancer Cell</i> , 2016, 29, 137-138.	16.8	9
212	HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC- Driven Medulloblastoma. <i>Cancer Cell</i> , 2016, 29, 311-323.	16.8	204
213	Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes. <i>Cancer Cell</i> , 2016, 29, 379-393.	16.8	438
214	New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. <i>Cell</i> , 2016, 164, 1060-1072.	28.9	702
215	Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. <i>Lancet Oncology</i> , The, 2016, 17, 484-495.	10.7	274
216	p53 and Medulloblastoma. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2016, 6, a026278.	6.2	29

#	ARTICLE	IF	CITATIONS
217	An epigenetic gateway to brain tumor cell identity. <i>Nature Neuroscience</i> , 2016, 19, 10-19.	14.8	76
218	Successful treatment of primary intracranial sarcoma with the ICE chemotherapy regimen and focal radiation in children. <i>Journal of Neurosurgery: Pediatrics</i> , 2016, 17, 298-302.	1.3	11
219	BRAF alteration status and the histone H3F3A gene K27M mutation segregate spinal cord astrocytoma histology. <i>Acta Neuropathologica</i> , 2016, 131, 147-150.	7.7	57
220	Checkpoint kinase 1 expression is an adverse prognostic marker and therapeutic target in MYC-driven medulloblastoma. <i>Oncotarget</i> , 2016, 7, 53881-53894.	1.8	17
221	Medulloblastoma-associated DDX3 variant selectively alters the translational response to stress. <i>Oncotarget</i> , 2016, 7, 28169-28182.	1.8	62
222	Norrin/Frizzled4 signalling in the preneoplastic niche blocks medulloblastoma initiation. <i>ELife</i> , 2016, 5, .	6.0	21
223	MPTH-26MOLECULAR REFINEMENT OF PEDIATRIC POSTERIOR FOSSA EPENDYMOMA. <i>Neuro-Oncology</i> , 2015, 17, v144.1-v144.	1.2	0
224	Dose-level response rates of mTOR inhibition in tuberous sclerosis complex related subependymal giant cell astrocytoma. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1754-1760.	1.5	16
225	Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. <i>Cancer Cell</i> , 2015, 27, 728-743.	16.8	933
226	Molecular Biology and Genetics of Medulloblastoma. , 2015, , 265-286.		0
227	Myocardial Fibrosis Burden Predicts Left Ventricular Ejection Fraction and Is Associated With Age and Steroid Treatment Duration in Duchenne Muscular Dystrophy. <i>Journal of the American Heart Association</i> , 2015, 4, .	3.7	114
228	Fingering the Correct Culprit: NonRANDOM Target Selection for Therapy of Neuroblastoma. <i>Trends in Cancer</i> , 2015, 1, 213-215.	7.4	0
229	Medulloblastoma subgroups remain stable across primary and metastatic compartments. <i>Acta Neuropathologica</i> , 2015, 129, 449-457.	7.7	80
230	<i>BRAF</i> Mutation and <i>CDKN2A</i> Deletion Define a Clinically Distinct Subgroup of Childhood Secondary High-Grade Glioma. <i>Journal of Clinical Oncology</i> , 2015, 33, 1015-1022.	1.6	244
231	Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers. <i>Nature Genetics</i> , 2015, 47, 257-262.	21.4	306
232	Molecular Characterization of Choroid Plexus Tumors Reveals Novel Clinically Relevant Subgroups. <i>Clinical Cancer Research</i> , 2015, 21, 184-192.	7.0	84
233	Preclinical target validation using patient-derived cells. <i>Nature Reviews Drug Discovery</i> , 2015, 14, 149-150.	46.4	46
234	Clinical implications of medulloblastoma subgroups: incidence of CSF diversion surgery. <i>Journal of Neurosurgery: Pediatrics</i> , 2015, 15, 236-242.	1.3	48

#	ARTICLE	IF	CITATIONS
235	Pediatric cancer genomics, a play rather than a portrait. <i>Nature Genetics</i> , 2015, 47, 851-852.	21.4	3
236	Neoadjuvant chemotherapy reduces blood loss during the resection of pediatric choroid plexus carcinomas. <i>Journal of Neurosurgery: Pediatrics</i> , 2015, 16, 126-133.	1.3	27
237	Visualization and segmentation of reciprocal cerebrocerebellar pathways in the healthy and injured brain. <i>Human Brain Mapping</i> , 2015, 36, 2615-2628.	3.6	22
238	Molecular subgroups of atypical teratoid rhabdoid tumours in children: an integrated genomic and clinicopathological analysis. <i>Lancet Oncology</i> , The, 2015, 16, 569-582.	10.7	147
239	Measuring the optical characteristics of medulloblastoma with optical coherence tomography. <i>Biomedical Optics Express</i> , 2015, 6, 1487.	2.9	13
240	Spinal Myxopapillary Ependymomas Demonstrate a Warburg Phenotype. <i>Clinical Cancer Research</i> , 2015, 21, 3750-3758.	7.0	40
241	EAG2 potassium channel with evolutionarily conserved function as a brain tumor target. <i>Nature Neuroscience</i> , 2015, 18, 1236-1246.	14.8	74
242	Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2560-2568.	4.1	55
243	Pathological Findings of a Subependymal Giant Cell Astrocytoma Following Treatment With Rapamycin. <i>Pediatric Neurology</i> , 2015, 53, 238-242.e1.	2.1	6
244	The Amazing and Deadly Glioma Race. <i>Cancer Cell</i> , 2015, 28, 275-277.	16.8	11
245	Posterior fossa ependymoma: current insights. <i>Child's Nervous System</i> , 2015, 31, 1699-1706.	1.1	29
246	Posterior fossa tumors in children: developmental anatomy and diagnostic imaging. <i>Child's Nervous System</i> , 2015, 31, 1661-1676.	1.1	63
247	Genetic and molecular alterations across medulloblastoma subgroups. <i>Journal of Molecular Medicine</i> , 2015, 93, 1075-1084.	3.9	51
248	MLL5 Orchestrates a Cancer Self-Renewal State by Repressing the Histone Variant H3.3 and Globally Reorganizing Chromatin. <i>Cancer Cell</i> , 2015, 28, 715-729.	16.8	90
249	Foretinib Is Effective Therapy for Metastatic Sonic Hedgehog Medulloblastoma. <i>Cancer Research</i> , 2015, 75, 134-146.	0.9	51
250	Embryonal Brain Tumors. , 2015, , 127-138.		4
251	Basic Science of Pediatric Brain Tumors. , 2015, , 59-67.		1
252	A microRNA-1280/JAG2 network comprises a novel biological target in high-risk medulloblastoma. <i>Oncotarget</i> , 2015, 6, 2709-2724.	1.8	24

#	ARTICLE	IF	CITATIONS
253	Mechanism of action and therapeutic efficacy of Aurora kinase B inhibition in MYC overexpressing medulloblastoma. <i>Oncotarget</i> , 2015, 6, 3359-3374.	1.8	23
254	Proteomic profiling of high risk medulloblastoma reveals functional biology. <i>Oncotarget</i> , 2015, 6, 14584-14595.	1.8	20
255	Identification of alsterpaullone as a novel small molecule inhibitor to target group 3 medulloblastoma. <i>Oncotarget</i> , 2015, 6, 21718-21729.	1.8	26
256	Characterization of novel biomarkers in selecting for subtype specific medulloblastoma phenotypes. <i>Oncotarget</i> , 2015, 6, 38881-38900.	1.8	22
257	Sleeping Beauty Mouse Models Identify Candidate Genes Involved in Gliomagenesis. <i>PLoS ONE</i> , 2014, 9, e113489.	2.5	21
258	Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma. <i>Oncotarget</i> , 2014, 5, 2355-2371.	1.8	103
259	Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tumor-initiating cells. <i>Acta Neuropathologica</i> , 2014, 128, 863-877.	7.7	34
260	Alternative lengthening of telomeres is enriched in, and impacts survival of TP53 mutant pediatric malignant brain tumors. <i>Acta Neuropathologica</i> , 2014, 128, 853-862.	7.7	46
261	Gene-expression profiling elucidates molecular signaling networks that can be therapeutically targeted in vestibular schwannoma. <i>Journal of Neurosurgery</i> , 2014, 121, 1434-1445.	1.6	35
262	ATM Regulates 3-Methylpurine-DNA Glycosylase and Promotes Therapeutic Resistance to Alkylating Agents. <i>Cancer Discovery</i> , 2014, 4, 1198-1213.	9.4	55
263	CS-01 * THE PHOSPHORYLATION OF ATOH1 LEADS TO ITS DEGRADATION MEDIATED BY THE E3 UBIQUITIN LIGASE HUWE1 IN GRANULE NEURON PROGENITORS. <i>Neuro-Oncology</i> , 2014, 16, v51-v51.	1.2	0
264	Molecular Insights into Pediatric Brain Tumors Have the Potential to Transform Therapy. <i>Clinical Cancer Research</i> , 2014, 20, 5630-5640.	7.0	124
265	An epigenetic therapy for diffuse intrinsic pontine gliomas. <i>Nature Medicine</i> , 2014, 20, 1378-1379.	30.7	25
266	De-escalation of therapy for pediatric medulloblastoma: Trade-offs between quality of life and survival. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1300-1304.	1.5	21
267	SnapShot: Medulloblastoma. <i>Cancer Cell</i> , 2014, 26, 940-940.e1.	16.8	24
268	WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma. <i>Acta Neuropathologica Communications</i> , 2014, 2, 174.	5.2	37
269	GE-16 * JAPANESE PEDIATRIC MOLECULAR NEURO-ONCOLOGY GROUP (JPMNG): ESTABLISHMENT OF A NATIONWIDE MOLECULAR DIAGNOSTIC NETWORK FOR PEDIATRIC MALIGNANT BRAIN TUMORS IN JAPAN. <i>Neuro-Oncology</i> , 2014, 16, v99-v100.	1.2	0
270	Neogenin1 is a sonic hedgehog target in medulloblastoma and is necessary for cell cycle progression. <i>International Journal of Cancer</i> , 2014, 134, 21-31.	5.1	26

#	ARTICLE	IF	CITATIONS
271	Treatment developments and the unfolding of the quality of life discussion in childhood medulloblastoma: a review. <i>Child's Nervous System</i> , 2014, 30, 979-990.	1.1	41
272	Polycomb group gene BMI1 controls invasion of medulloblastoma cells and inhibits BMP-regulated cell adhesion. <i>Acta Neuropathologica Communications</i> , 2014, 2, 10.	5.2	29
273	Duration of the pre-diagnostic interval in medulloblastoma is subgroup dependent. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1190-1194.	1.5	42
274	Genome Sequencing of SHH Medulloblastoma Predicts Genotype-Related Response to Smoothed Inhibition. <i>Cancer Cell</i> , 2014, 25, 393-405.	16.8	627
275	Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort. <i>Acta Neuropathologica</i> , 2014, 128, 137-149.	7.7	125
276	Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing. <i>Nature</i> , 2014, 510, 537-541.	27.8	378
277	Embryonal tumor with abundant neuropil and true rosettes (ETANTR), ependymoblastoma, and medulloepithelioma share molecular similarity and comprise a single clinicopathological entity. <i>Acta Neuropathologica</i> , 2014, 128, 279-289.	7.7	191
278	Fusion of TTYH1 with the C19MC microRNA cluster drives expression of a brain-specific DNMT3B isoform in the embryonal brain tumor ETMR. <i>Nature Genetics</i> , 2014, 46, 39-44.	21.4	167
279	The G protein α subunit G_{i2} is a tumor suppressor in Sonic hedgehog-driven medulloblastoma. <i>Nature Medicine</i> , 2014, 20, 1035-1042.	30.7	110
280	The Shh Receptor Boc Promotes Progression of Early Medulloblastoma to Advanced Tumors. <i>Developmental Cell</i> , 2014, 31, 34-47.	7.0	43
281	Shh Signaling Protects Atoh1 from Degradation Mediated by the E3 Ubiquitin Ligase Huwe1 in Neural Precursors. <i>Developmental Cell</i> , 2014, 29, 649-661.	7.0	71
282	Epigenetic States of Cells of Origin and Tumor Evolution Drive Tumor-Initiating Cell Phenotype and Tumor Heterogeneity. <i>Cancer Research</i> , 2014, 74, 4864-4874.	0.9	20
283	Genetic drivers of metastatic dissemination in sonic hedgehog medulloblastoma. <i>Acta Neuropathologica Communications</i> , 2014, 2, 85.	5.2	27
284	Cytogenetic Prognostication Within Medulloblastoma Subgroups. <i>Journal of Clinical Oncology</i> , 2014, 32, 886-896.	1.6	263
285	CNS-PNETs with C19MC amplification and/or LIN28 expression comprise a distinct histogenetic diagnostic and therapeutic entity. <i>Acta Neuropathologica</i> , 2014, 128, 291-303.	7.7	141
286	Integrated genomic analysis identifies the mitotic checkpoint kinase WEE1 as a novel therapeutic target in medulloblastoma. <i>Molecular Cancer</i> , 2014, 13, 72.	19.2	62
287	Impact of Craniospinal Dose, Boost Volume, and Neurologic Complications on Intellectual Outcome in Patients With Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 1760-1768.	1.6	177
288	Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma. <i>Nature</i> , 2014, 511, 428-434.	27.8	520

#	ARTICLE	IF	CITATIONS
289	Quiescent Sox2+ Cells Drive Hierarchical Growth and Relapse in Sonic Hedgehog Subgroup Medulloblastoma. <i>Cancer Cell</i> , 2014, 26, 33-47.	16.8	241
290	Overcoming resistance to sonic hedgehog inhibition by targeting p90 ribosomal S6 kinase in pediatric medulloblastoma. <i>Pediatric Blood and Cancer</i> , 2014, 61, 107-115.	1.5	39
291	<i>Bmi1</i> overexpression in the cerebellar granule cell lineage of mice affects cell proliferation and survival without initiating medulloblastoma formation. <i>DMM Disease Models and Mechanisms</i> , 2013, 6, 49-63.	2.4	15
292	Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. <i>Nature Genetics</i> , 2013, 45, 927-932.	21.4	674
293	Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays. <i>Acta Neuropathologica</i> , 2013, 125, 913-916.	7.7	244
294	DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies. <i>Acta Neuropathologica</i> , 2013, 125, 359-371.	7.7	133
295	Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma. <i>Acta Neuropathologica</i> , 2013, 125, 373-384.	7.7	169
296	FoxG1 Interacts with Bmi1 to Regulate Self-Renewal and Tumorigenicity of Medulloblastoma Stem Cells. <i>Stem Cells</i> , 2013, 31, 1266-1277.	3.2	53
297	Emerging Insights into the Ependymoma Epigenome. <i>Brain Pathology</i> , 2013, 23, 206-209.	4.1	21
298	Hypermethylation of the Inactive X Chromosome Is a Frequent Event in Cancer. <i>Cell</i> , 2013, 155, 567-581.	28.9	67
299	Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. <i>Lancet Oncology</i> , The, 2013, 14, 1200-1207.	10.7	307
300	Targeting Sonic Hedgehog-Associated Medulloblastoma through Inhibition of Aurora and Polo-like Kinases. <i>Cancer Research</i> , 2013, 73, 6310-6322.	0.9	52
301	Personalizing the Treatment of Pediatric Medulloblastoma: Polo-like Kinase 1 as a Molecular Target in High-Risk Children. <i>Cancer Research</i> , 2013, 73, 6734-6744.	0.9	79
302	ABC transporter activity linked to radiation resistance and molecular subtype in pediatric medulloblastoma. <i>Experimental Hematology and Oncology</i> , 2013, 2, 26.	5.0	36
303	MyoD Is a Tumor Suppressor Gene in Medulloblastoma. <i>Cancer Research</i> , 2013, 73, 6828-6837.	0.9	21
304	MicroRNA 218 Acts as a Tumor Suppressor by Targeting Multiple Cancer Phenotype-associated Genes in Medulloblastoma. <i>Journal of Biological Chemistry</i> , 2013, 288, 1918-1928.	3.4	100
305	Canonical $\text{TGF}\beta^2$ Pathway Activity Is a Predictor of SHH -Driven Medulloblastoma Survival and Delineates Putative Precursors in Cerebellar Development. <i>Brain Pathology</i> , 2013, 23, 178-191.	4.1	26
306	Deconstruction of Medulloblastoma Cellular Heterogeneity Reveals Differences between the Most Highly Invasive and Self-Renewing Phenotypes. <i>Neoplasia</i> , 2013, 15, 384-IN8.	5.3	38

#	ARTICLE	IF	CITATIONS
307	The eEF2 Kinase Confers Resistance to Nutrient Deprivation by Blocking Translation Elongation. <i>Cell</i> , 2013, 153, 1064-1079.	28.9	348
308	Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study. <i>Lancet Oncology</i> , The, 2013, 14, 534-542.	10.7	212
309	Somatostatin receptor subtype 2 (sst2) is a potential prognostic marker and a therapeutic target in medulloblastoma. <i>Child's Nervous System</i> , 2013, 29, 1253-1262.	1.1	12
310	TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. <i>Acta Neuropathologica</i> , 2013, 126, 917-929.	7.7	146
311	Medulloblastoma invading the transverse sinus. <i>Journal of Neurosurgery: Pediatrics</i> , 2013, 12, 325-327.	1.3	1
312	Medulloblastoma molecular dissection. <i>Current Opinion in Oncology</i> , 2013, 25, 674-681.	2.4	54
313	<i>Sleeping Beauty</i> mutagenesis in a mouse medulloblastoma model defines networks that discriminate between human molecular subgroups. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, E4325-34.	7.1	62
314	<i>Notch1</i> -Induced Brain Tumor Models the Sonic Hedgehog Subgroup of Human Medulloblastoma. <i>Cancer Research</i> , 2013, 73, 5381-5390.	0.9	29
315	Subgroup-Specific Prognostic Implications of <i>TP53</i> Mutation in Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 2927-2935.	1.6	381
316	G-protein coupled receptor expression patterns delineate medulloblastoma subgroups. <i>Acta Neuropathologica Communications</i> , 2013, 1, 66.	5.2	22
317	Intertumoral and Intratumoral Heterogeneity as a Barrier for Effective Treatment of Medulloblastoma. <i>Neurosurgery</i> , 2013, 60, 57-63.	1.1	13
318	Anaplastic medulloblastoma in a child with Duchenne muscular dystrophy. <i>Journal of Neurosurgery: Pediatrics</i> , 2012, 10, 21-24.	1.3	5
319	CXCR4 Activation Defines a New Subgroup of Sonic Hedgehog-Driven Medulloblastoma. <i>Cancer Research</i> , 2012, 72, 122-132.	0.9	58
320	Functional Genomics Identifies Drivers of Medulloblastoma Dissemination. <i>Cancer Research</i> , 2012, 72, 4944-4953.	0.9	44
321	Voltage-gated potassium channel EAG2 controls mitotic entry and tumor growth in medulloblastoma via regulating cell volume dynamics. <i>Genes and Development</i> , 2012, 26, 1780-1796.	5.9	68
322	Monoallelic Expression Determines Oncogenic Progression and Outcome in Benign and Malignant Brain Tumors. <i>Cancer Research</i> , 2012, 72, 636-644.	0.9	56
323	Subgroup-specific structural variation across 1,000 medulloblastoma genomes. <i>Nature</i> , 2012, 488, 49-56.	27.8	761
324	Clinical and neuroanatomical predictors of cerebellar mutism syndrome. <i>Neuro-Oncology</i> , 2012, 14, 1294-1303.	1.2	112

#	ARTICLE	IF	CITATIONS
325	WIP1 Enhances Tumor Formation in a Sonic Hedgehog-Dependent Model of Medulloblastoma. <i>Neurosurgery</i> , 2012, 70, 1003-1010.	1.1	21
326	Medulloblastomics: the end of the beginning. <i>Nature Reviews Cancer</i> , 2012, 12, 818-834.	28.4	560
327	Matching mice to malignancy: molecular subgroups and models of medulloblastoma. <i>Child's Nervous System</i> , 2012, 28, 521-532.	1.1	19
328	Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples. <i>Acta Neuropathologica</i> , 2012, 123, 615-626.	7.7	318
329	Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma. <i>Cancer Cell</i> , 2012, 22, 425-437.	16.8	1,551
330	Survival Benefit for Pediatric Patients With Recurrent Ependymoma Treated With Reirradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 1541-1548.	0.8	111
331	Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. <i>Nature</i> , 2012, 488, 106-110.	27.8	675
332	Multiple CDK/CYCLIND genes are amplified in medulloblastoma and supratentorial primitive neuroectodermal brain tumor. <i>Cancer Genetics</i> , 2012, 205, 220-231.	0.4	25
333	Genome Sequencing of Pediatric Medulloblastoma Links Catastrophic DNA Rearrangements with TP53 Mutations. <i>Cell</i> , 2012, 148, 59-71.	28.9	743
334	Nestin Expression Identifies Ependymoma Patients with Poor Outcome. <i>Brain Pathology</i> , 2012, 22, 848-860.	4.1	40
335	Molecular subgroups of medulloblastoma. <i>Expert Review of Neurotherapeutics</i> , 2012, 12, 871-884.	2.8	142
336	The RNA-Binding Protein Musashi1 Affects Medulloblastoma Growth via a Network of Cancer-Related Genes and Is an Indicator of Poor Prognosis. <i>American Journal of Pathology</i> , 2012, 181, 1762-1772.	3.8	73
337	ICGC PedBrain - dissecting the genomic complexity underlying medulloblastoma using whole-genome sequencing. <i>BMC Proceedings</i> , 2012, 6, .	1.6	1
338	The clinical implications of medulloblastoma subgroups. <i>Nature Reviews Neurology</i> , 2012, 8, 340-351.	10.1	261
339	Clonal selection drives genetic divergence of metastatic medulloblastoma. <i>Nature</i> , 2012, 482, 529-533.	27.8	376
340	The Epigenetics of Brain Tumors. <i>Methods in Molecular Biology</i> , 2012, 863, 139-153.	0.9	38
341	Dissecting the genomic complexity underlying medulloblastoma. <i>Nature</i> , 2012, 488, 100-105.	27.8	765
342	Targeting the enhancer of zeste homologue 2 in medulloblastoma. <i>International Journal of Cancer</i> , 2012, 131, 1800-1809.	5.1	71

#	ARTICLE	IF	CITATIONS
343	Genome-Wide Methylation Analysis. <i>Methods in Molecular Biology</i> , 2012, 863, 303-317.	0.9	2
344	Biological and clinical heterogeneity of MYCN-amplified medulloblastoma. <i>Acta Neuropathologica</i> , 2012, 123, 515-527.	7.7	66
345	Molecular subgroups of medulloblastoma: the current consensus. <i>Acta Neuropathologica</i> , 2012, 123, 465-472.	7.7	1,536
346	MicroRNA-182 promotes leptomeningeal spread of non-sonic hedgehog-medulloblastoma. <i>Acta Neuropathologica</i> , 2012, 123, 529-538.	7.7	60
347	Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. <i>Acta Neuropathologica</i> , 2012, 123, 473-484.	7.7	863
348	Subgroup-specific alternative splicing in medulloblastoma. <i>Acta Neuropathologica</i> , 2012, 123, 485-499.	7.7	28
349	An Animal Model of MYC-Driven Medulloblastoma. <i>Cancer Cell</i> , 2012, 21, 155-167.	16.8	267
350	Distinct Neural Stem Cell Populations Give Rise to Disparate Brain Tumors in Response to N-MYC. <i>Cancer Cell</i> , 2012, 21, 601-613.	16.8	177
351	Polo-like kinase 1 (PLK1) inhibition suppresses cell growth and enhances radiation sensitivity in medulloblastoma cells. <i>BMC Cancer</i> , 2012, 12, 80.	2.6	69
352	Adult Medulloblastoma Comprises Three Major Molecular Variants. <i>Journal of Clinical Oncology</i> , 2011, 29, 2717-2723.	1.6	215
353	Rapid Diagnosis of Medulloblastoma Molecular Subgroups. <i>Clinical Cancer Research</i> , 2011, 17, 1883-1894.	7.0	69
354	The Genetic Landscape of the Childhood Cancer Medulloblastoma. <i>Science</i> , 2011, 331, 435-439.	12.6	652
355	FISH and chips: the recipe for improved prognostication and outcomes for children with medulloblastoma. <i>Cancer Genetics</i> , 2011, 204, 577-588.	0.4	50
356	Delineation of Two Clinically and Molecularly Distinct Subgroups of Posterior Fossa Ependymoma. <i>Cancer Cell</i> , 2011, 20, 143-157.	16.8	494
357	PCDH10 is a candidate tumour suppressor gene in medulloblastoma. <i>Child's Nervous System</i> , 2011, 27, 1243-1249.	1.1	21
358	Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct. <i>Acta Neuropathologica</i> , 2011, 122, 231-240.	7.7	195
359	Intracerebral malignant peripheral nerve sheath tumor in a child with neurofibromatosis Type 1 and middle cerebral artery aneurysm treated with endovascular coil embolization. <i>Journal of Neurosurgery: Pediatrics</i> , 2011, 8, 346-352.	1.3	15
360	<i>FSTL5</i> Is a Marker of Poor Prognosis in Non-WNT/Non-SHH Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 3852-3861.	1.6	143

#	ARTICLE	IF	CITATIONS
361	Medulloblastoma Comprises Four Distinct Molecular Variants. <i>Journal of Clinical Oncology</i> , 2011, 29, 1408-1414.	1.6	1,131
362	Reply to J.C. Lindsey et al. <i>Journal of Clinical Oncology</i> , 2011, 29, e348-e349.	1.6	2
363	Reply to J.C. Lindsey et al. <i>Journal of Clinical Oncology</i> , 2011, 29, e347-e347.	1.6	2
364	Neurosurgical management of extraaxial central nervous system infections in children. <i>Journal of Neurosurgery: Pediatrics</i> , 2011, 7, 441-451.	1.3	44
365	Mouse models of medulloblastoma. <i>Chinese Journal of Cancer</i> , 2011, 30, 442-449.	4.9	38
366	Molecular genetics of ependymoma. <i>Chinese Journal of Cancer</i> , 2011, 30, 669-681.	4.9	37
367	Posterior fossa ependymomas: new radiological classification with surgical correlation. <i>Child's Nervous System</i> , 2010, 26, 1765-1772.	1.1	28
368	Molecular diagnostics of CNS embryonal tumors. <i>Acta Neuropathologica</i> , 2010, 120, 553-566.	7.7	83
369	The Genetics of Pediatric Brain Tumors. <i>Current Neurology and Neuroscience Reports</i> , 2010, 10, 215-223.	4.2	69
370	Cross-species genomics matches driver mutations and cell compartments to model ependymoma. <i>Nature</i> , 2010, 466, 632-636.	27.8	324
371	<i>TP53</i> Mutation Is Frequently Associated With <i>CTNNB1</i> Mutation or <i>MYCN</i> Amplification and Is Compatible With Long-Term Survival in Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 5188-5196.	1.6	100
372	Universal Poor Survival in Children With Medulloblastoma Harboring Somatic <i>TP53</i> Mutations. <i>Journal of Clinical Oncology</i> , 2010, 28, 1345-1350.	1.6	148
373	Role of LIM and SH3 Protein 1 (LASP1) in the Metastatic Dissemination of Medulloblastoma. <i>Cancer Research</i> , 2010, 70, 8003-8014.	0.9	62
374	Pleiotropic role for <i>MYCN</i> in medulloblastoma. <i>Genes and Development</i> , 2010, 24, 1059-1072.	5.9	146
375	Genomics of medulloblastoma: from Giemsa-banding to next-generation sequencing in 20 years. <i>Neurosurgical Focus</i> , 2010, 28, E6.	2.3	48
376	Silencing of Thrombospondin-1 Is Critical for Myc-Induced Metastatic Phenotypes in Medulloblastoma. <i>Cancer Research</i> , 2010, 70, 8199-8210.	0.9	54
377	HDAC5 and HDAC9 in Medulloblastoma: Novel Markers for Risk Stratification and Role in Tumor Cell Growth. <i>Clinical Cancer Research</i> , 2010, 16, 3240-3252.	7.0	175
378	Use of ifosfamide, carboplatin, and etoposide chemotherapy in choroid plexus carcinoma. <i>Journal of Neurosurgery: Pediatrics</i> , 2010, 5, 615-621.	1.3	65

#	ARTICLE	IF	CITATIONS
379	Genetic and Epigenetic Inactivation of Kruppel-like Factor 4 in Medulloblastoma. Neoplasia, 2010, 12, 20-27.	5.3	69
380	Calculating a cure for cancer: managing medulloblastoma MATH1-ernatically. Expert Review of Neurotherapeutics, 2010, 10, 1489-1492.	2.8	7
381	OTX2 Is Critical for the Maintenance and Progression of Shh-Independent Medulloblastomas. Cancer Research, 2010, 70, 181-191.	0.9	104
382	Abstract 4347: Medulloblastoma comprises four distinct diseases. , 2010, , .		6
383	MicroRNA-199b-5p Impairs Cancer Stem Cells through Negative Regulation of HES1 in Medulloblastoma. PLoS ONE, 2009, 4, e4998.	2.5	233
384	Normal and oncogenic roles for microRNAs in the developing brain. Cell Cycle, 2009, 8, 4049-4054.	2.6	30
385	YAP1 is amplified and up-regulated in hedgehog-associated medulloblastomas and mediates Sonic hedgehog-driven neural precursor proliferation. Genes and Development, 2009, 23, 2729-2741.	5.9	332
386	Tuberous Sclerosis Complex Suppression in Cerebellar Development and Medulloblastoma: Separate Regulation of Mammalian Target of Rapamycin Activity and p27Kip1 Localization. Cancer Research, 2009, 69, 7224-7234.	0.9	37
387	Frequent Amplification of a chr19q13.41 MicroRNA Polycistron in Aggressive Primitive Neuroectodermal Brain Tumors. Cancer Cell, 2009, 16, 533-546.	16.8	207
388	The genetic and epigenetic basis of ependymoma. Child's Nervous System, 2009, 25, 1195-1201.	1.1	73
389	Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma. Nature Genetics, 2009, 41, 465-472.	21.4	391
390	The miR-17/92 Polycistron Is Up-regulated in Sonic Hedgehog-Driven Medulloblastomas and Induced by N-myc in Sonic Hedgehog-Treated Cerebellar Neural Precursors. Cancer Research, 2009, 69, 3249-3255.	0.9	273
391	An Epigenetic Genome-Wide Screen Identifies SPINT2 as a Novel Tumor Suppressor Gene in Pediatric Medulloblastoma. Cancer Research, 2008, 68, 9945-9953.	0.9	95
392	Expression of MAGE and GAGE genes in medulloblastoma and modulation of resistance to chemotherapy. Journal of Neurosurgery: Pediatrics, 2008, 1, 305-313.	1.3	40
393	THE HISTORY OF NEUROSURGERY AT THE HOSPITAL FOR SICK CHILDREN IN TORONTO. Neurosurgery, 2007, 61, 612-625.	1.1	15
394	Incorporation of C-1 lateral mass screws in occipitocervical and atlantoaxial fusions for children 8 years of age or younger. Journal of Neurosurgery: Pediatrics, 2007, 107, 178-183.	1.3	28
395	Genomics Identifies Medulloblastoma Subgroups That Are Enriched for Specific Genetic Alterations. Journal of Clinical Oncology, 2006, 24, 1924-1931.	1.6	617
396	Genetics of choroid plexus tumors. Neurosurgical Focus, 2006, 20, 1-3.	2.3	16

#	ARTICLE	IF	CITATIONS
397	Radial glia cells are candidate stem cells of ependymoma. <i>Cancer Cell</i> , 2005, 8, 323-335.	16.8	758
398	Retrospective family study of childhood medulloblastoma. <i>American Journal of Medical Genetics, Part A</i> , 2005, 134A, 399-403.	1.2	27
399	Detection of Active Coronary Arterial Vasculitis Using Magnetic Resonance Imaging in Kawasaki Disease. <i>Circulation</i> , 2005, 112, .	1.6	9
400	Atypical Teratoid/Rhabdoid Tumors. , 2005, , 744-750.		0
401	Identification of differentially expressed and developmentally regulated genes in medulloblastoma using suppression subtraction hybridization. <i>Oncogene</i> , 2004, 23, 3444-3453.	5.9	144
402	Failure of a medulloblastoma-derived mutant of SUFU to suppress WNT signaling. <i>Oncogene</i> , 2004, 23, 4577-4583.	5.9	75
403	Molecular pathogenesis of childhood brain tumors. <i>Journal of Neuro-Oncology</i> , 2004, 70, 203-215.	2.9	51
404	The RAG-1/2 endonuclease causes genomic instability and controls CNS complications of lymphoblastic leukemia in p53/Prkdc-deficient mice. <i>Cancer Cell</i> , 2003, 3, 37-50.	16.8	73
405	Transcriptional profiling of medulloblastoma in children. <i>Journal of Neurosurgery</i> , 2003, 99, 534-541.	1.6	36
406	Bioinformatics in Neurosurgery. <i>Neurosurgery</i> , 2003, 52, 723-731.	1.1	5
407	Advanced Cancer Genetics in Neurosurgical Research. <i>Neurosurgery</i> , 2003, 53, 1168-1178.	1.1	2
408	Mutations in SUFU predispose to medulloblastoma. <i>Nature Genetics</i> , 2002, 31, 306-310.	21.4	722
409	Awake Craniotomy for Removal of Intracranial Tumor: Considerations for Early Discharge. <i>Anesthesia and Analgesia</i> , 2001, 92, 89-94.	2.2	149
410	Cip/Kip cell-cycle inhibitors: a neuro-oncological perspective. <i>Journal of Neuro-Oncology</i> , 2001, 51, 205-218.	2.9	15
411	Molecular genetics of pineal region neoplasms. <i>Journal of Neuro-Oncology</i> , 2001, 54, 219-238.	2.9	18
412	Medulloblastoma in a Child with Rubenstein-Taybi Syndrome: Case Report and Review of the Literature. <i>Pediatric Neurosurgery</i> , 2001, 35, 235-238.	0.7	36
413	Molecular Insight into Medulloblastoma and Central Nervous System Primitive Neuroectodermal Tumor Biology from Hereditary Syndromes: A Review. <i>Neurosurgery</i> , 2000, 47, 888-901.	1.1	110
414	Perspectives in pediatric neurosurgery. <i>Child's Nervous System</i> , 2000, 16, 809-820.	1.1	6

#	ARTICLE	IF	CITATIONS
415	Molecular cytogenetic analysis of medulloblastomas and supratentorial primitive neuroectodermal tumors by using conventional banding, comparative genomic hybridization, and spectral karyotyping. Journal of Neurosurgery, 2000, 93, 437-448.	1.6	124
416	Familial Posterior Fossa Brain Tumors of Infancy Secondary to Germline Mutation of the hSNF5 Gene. American Journal of Human Genetics, 2000, 66, 1403-1406.	6.2	170
417	The hPMS2 exon 5 mutation and malignant glioma. Journal of Neurosurgery, 1999, 90, 946-950.	1.6	24
418	Awake craniotomy with brain mapping as the routine surgical approach to treating patients with supratentorial intraaxial tumors: a prospective trial of 200 cases. Journal of Neurosurgery, 1999, 90, 35-41.	1.6	429
419	Basal Suppression of Sonic Hedgehog Pathway by the G-Protein-Coupled Receptor Gpr161 Restricts Medulloblastoma Pathogenesis. SSRN Electronic Journal, 0, , .	0.4	0